Literature DB >> 3571889

Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.

B P Buggy, R Fekety, J Silva.   

Abstract

Seven patients with multiple bacteriologic and symptomatic relapses of Clostridium difficile-associated diarrhea and/or colitis were treated with vancomycin and rifampin in combination. Diarrhea and abdominal pain promptly resolved in all, and neither C. difficile nor its toxin could be recovered from their stools shortly after therapy. However, stools of all patients subsequently became culture-positive for C. difficile and occasionally had demonstrable cytotoxin. Except in one instance following oral antibiotic use, all patients remained free of symptoms. Resistance to either vancomycin or rifampin was not encountered. Biotyping of isolates with clostridial bacteriophages and bacteriocins suggested true relapse with the same organism in all patients studied, rather than reinfection with another strain. Vancomycin and rifampin in combination appear to be useful in the therapy of relapsing antibiotic-associated diarrhea due to C. difficile.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571889     DOI: 10.1097/00004836-198704000-00009

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

Review 1.  Recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; C P Kelly
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  In vitro synergy studies with Clostridium difficile.

Authors:  A E Bacon; S McGrath; R Fekety; W J Holloway
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

Review 4.  Clostridium difficile-associated colitis.

Authors:  Mark W Hull; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-11       Impact factor: 3.275

5.  Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Authors:  Patima Permpoonpattana; Huynh A Hong; Jutarop Phetcharaburanin; Jen-Min Huang; Jenny Cook; Neil F Fairweather; Simon M Cutting
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

Review 6.  Update on pseudomembranous colitis.

Authors:  J Silva
Journal:  West J Med       Date:  1989-12

7.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.

Authors:  George Tannous; Guy Neff; Nyingi Kemmer
Journal:  Case Rep Gastroenterol       Date:  2010-09-28

Review 9.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.